Literature DB >> 24672595

Lemierre's Syndrome.

Jayten Shook1, Christopher Trigger1.   

Abstract

Entities:  

Mesh:

Year:  2014        PMID: 24672595      PMCID: PMC3966442          DOI: 10.5811/westjem.2013.12.20418

Source DB:  PubMed          Journal:  West J Emerg Med        ISSN: 1936-900X


× No keyword cloud information.
A 25-year-old woman presented to the emergency department (ED) with 4 days of progressive, left-sided neck pain and swelling. Additional symptoms included sore throat, dysphagia and left otalgia. On presentation she was tachycardic, hypotensive and had an exam notable for granular pharyngitis as well as a large area of nonfluctuant induration and swelling posterior to her left mandibular angle (Figure 1). Diffuse anterior and posterior cervical lymphadenopathy was palpable on the left. She had a white blood cell count of 13.4 with a left shift and no bandemia. A computed tomography (CT) of the neck with intravenous contrast was also performed (Figure 2).
Figure 1

Large mass on left lateral neck.

Figure 2

Coronal computed tomography of the neck with contrast demonstrating a 3.3 cm loculated abscess (*) in the left posterior triangle with adjacent cervical adenitis and left internal jugular vein occlusion.

Lemierre’s syndrome, also called postanginal septicemia, is a rare but potentially fatal disease characterized by septic thrombophlebitis of the internal jugular vein. Affected patients are typically young, otherwise healthy individuals with a recent history of tonsillitis (37%) or pharyngitis (30%) followed by severe sepsis.1–2 Patients often present with complaints of sore throat, neck pain or neck mass as well as bone and joint pain related to septic emboli. The primary infection progresses to abscess formation within 1–3 weeks, facilitating invasion of the parapharyngeal space and internal jugular vein, leading to septic thrombophlebitis. The disease is often complicated by septic emboli traveling to the lungs and large joints. Isolated organisms include anaerobic pathogens, with Fusobacterium necrophorum being the most common.2 Early recognition and treatment are crucial as the mortality rate in untreated individuals approaches 17%. Antibiotic treatment should include intravenous anaerobic coverage with metronidazole or clindamycin which can be transitioned to oral with minimum treatment duration of 3 weeks. Anticoagulation in Lemierre’s syndrome remains controversial but should be considered if thrombosis extension is noted clinically.2 The imaging modality of choice is a contrast enhanced CT of the neck. Radiologic findings include intraluminal venous filling defects and peripheral rim enhancement of the involved segment which can measure 10–20 cm in length and most frequently includes complete occlusion.3
  2 in total

1.  Thrombophlebitis of the internal jugular vein (Lemierre syndrome): clinical and CT findings.

Authors:  Bo Yeon Kim; Dae Young Yoon; Hyeong Chul Kim; Eun Soo Kim; Sora Baek; Kyoung Ja Lim; Young Lan Seo; Eun Joo Yun; Chul Soon Choi; Sang Hoon Bae
Journal:  Acta Radiol       Date:  2013-04-30       Impact factor: 1.990

Review 2.  Lemierre's syndrome: A systematic review.

Authors:  Peter D Karkos; Sheetal Asrani; Christos D Karkos; Samuel C Leong; Evangelia G Theochari; Thalia D Alexopoulou; Assimakis D Assimakopoulos
Journal:  Laryngoscope       Date:  2009-08       Impact factor: 3.325

  2 in total
  3 in total

1.  Thrombosis of the internal jugular vein.

Authors:  Lloyd Isaac Tannenbaum; Michael David April; Robert Edward Watts; Nadia Mary Pearson
Journal:  Intern Emerg Med       Date:  2015-09-05       Impact factor: 3.397

2.  Some neck swellings are serious; a case of Lemierre's Syndrome.

Authors:  Ali Raza Ghani; Mohsin Hamid; Ahsan Raza; Rizwan Naseer; Joseph Crocetti
Journal:  J Community Hosp Intern Med Perspect       Date:  2017-09-19

Review 3.  Lemierre's syndrome: current perspectives on diagnosis and management.

Authors:  Katrine M Johannesen; Uffe Bodtger
Journal:  Infect Drug Resist       Date:  2016-09-14       Impact factor: 4.003

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.